Overview

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

Status:
NOT_YET_RECRUITING
Trial end date:
2031-06-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed * Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
Phase:
PHASE3
Details
Lead Sponsor:
Alnylam Pharmaceuticals